"The war against hospital superbugs is turning nasty, and Kevin Judice wants his company on the front lines.

Achaogen Inc. started a Phase I trial Jan. 26 that focuses on next-generation antibacterials, which the company calls neoglycosides, to treat hospital-based infections. It could be “the big hammer,” CEO Judice said, against potential killer superbugs like methicillin-resistant Staphylococcus aureus, or MRSA."
Ron Leuty
San Francisco Business Times
January 30, 2009
Read more...